Turning Point Therapeutics (TPTX) – The biopharmaceutical company’s shares more than doubled in premarket trading after agreeing to be acquired by Bristol Myers Squibb (BMY) for $76 per share in cash, or $4.1 billion. Turning Point specializes in cancer treatments. UP $40 premarket!
Bull-markets are born on pessimism, grow on skepticism, mature on optimism and die on euphoria .. Sir John Templeton Make your Life a Mission .... NOT an Intermission. † §|PL1|§